公告称，转盈为亏主要由于本期间预期取得集团按公允价值计入损益的金融资产的公允价值亏损约706 万港元，相比2024年同期的公允价值收益约1508.2万港元。该集团按公允价值计入损益的金融资产为集 团持有的若干出门问问有限公司于香港联合交易所有限公司上市的普通股份(股份代号：2438)，其公允 价值乃参照出门问问的普通股份市值而估算。尽管本期间集团业务营运所产生的亏损与2024年同期相应 的集团业务营运所产生的亏损相比有所减少，上述集团按公允价值计入损益的金融资产的公允价值亏损 预期导致本期间由盈转亏。 圆美光电(08311)公布，预期2025年上半年该集团财务业绩将转盈为亏，取得公司权益持有人应占综合 亏损约1200万港元至1400万港元，2024年上半年公司权益持有人应占综合利润约225万港元。 ...

Core Viewpoint - On its 30th anniversary, Shuanglu Pharmaceutical is facing a historic turning point, reporting a net loss of approximately 74.07 million yuan for 2024, marking its first annual loss since its listing in 2004 [1][4]. Financial Performance - In 2024, Shuanglu Pharmaceutical achieved an operating revenue of approximately 660 million yuan, a year-on-year decline of 35.15%, with a corresponding net profit of -74.07 million yuan, transitioning from profit to loss [4]. - The company had previously seen net profits exceeding 100 million yuan since 2007, peaking at 695 million yuan in 2014, and fluctuating between 200 million and 500 million yuan from 2020 to 2023 [4]. - In the first quarter of 2024, the company reported an operating revenue of approximately 169 million yuan, down 31.1%, and a net profit of approximately 45.97 million yuan, down 34.46% [4]. Product Sales Decline - Multiple key products experienced significant sales declines in 2024, with the oncology and immune regulation products generating sales of 276 million yuan, accounting for 42.69% of total sales, down 27.69% year-on-year [6]. - The sales of the previously promising product, Lenalidomide, accounted for only 4.89% of the oncology product category, with a staggering year-on-year decline of 77.22% [6][7]. - Other product categories, including anti-infection, trauma repair, and cardiovascular products, also saw sales declines of 48.42%, 30.95%, and 33.92% respectively [7]. Financial Asset Impact - The decline in financial assets, particularly the fair value changes in securities investments, significantly impacted the company's performance, with a total loss of approximately 178 million yuan from its holdings in Fosun Pharma, Shouyao Holdings, and Xinghao Pharma [9]. - The fair value changes for these stocks were -22.94 thousand yuan, -161 million yuan, and -16.14 million yuan respectively, contributing to the overall financial downturn [9]. Future Outlook - The company plans to increase R&D investment and has developed a strong product pipeline in oncology, liver disease, antiviral, metabolic regulation, and cardiovascular fields, while also exploring new areas such as diabetes and ophthalmology [5]. - The chairman expressed optimism that the company will recover its performance, viewing 2025 as a year of both challenges and opportunities [5][10].